Screener / SEC EDGAR /CIK 0001743881 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

BridgeBio Pharma, Inc. BBIO

Compare with peers Embed
FY2025 at a glance

Sales up 126.3%, free cash flow up to -$447.0M

XBRL, from each 10-K
RevenueStatements
$502.1M from $221.9M in FY2024
FY2017FY2025
Net incomeStatements
-$724.9M from -$535.8M in FY2024
FY2017FY2025
Free cash flowStatements
-$447.0M from -$521.7M in FY2024
FY2017FY2025
EPS (diluted)Statements
$-3.78 from $-2.88 in FY2024
FY2017FY2025
Operating marginStatements
-104.2% from -267.2% in FY2024
FY2017FY2025
Total debtStatements
$2.0B from $437.3M in FY2024
FY2017FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (37)
EPS (ttm)
-3.03
Sales (ttm)
945.5M
Net income (ttm)
-592.1M
Sales growth
+126%
EPS growth
-
Sales Q/Q
+193%
Free cash flow
-369.8M
Gross margin
94.3%
Oper. margin
-38.5%
Net margin
-62.6%
FCF margin
-39.1%
ROE
n/m
R&D / sales
90.0%
Dividend
-
Debt/Eq
n/m
Curr. ratio
2.09
Cash
1.5B
Op. cash flow (ttm)
-369.0M
EBITDA
-518.0M
EBITDA margin
-103.2%
Net debt
1.1B
Quick ratio
2.06
Interest cover
-9.86
FCF after stock pay
-580.0M
Oper. margin low 5y
-6528.8%
Stock pay / sales
26.5%
Shares out.
194.8M
Shares Y/Y
+2.9%
Book / share
-8.53
Cash / share
7.87
Sales / share
4.85
Asset turnover
0.44
Inventory turns
0.78
Days sales out.
101
Sales 3Y CAGR
+86.3%
Sales 5Y CAGR
+127%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 502.1M +52.1% a year Net income -724.9M
FY2019 revenue 40.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-22-002030 FY2019 net income -260.6M · NetIncomeLossAvailableToCommonStockholdersBasic, 0000950170-22-002030 40.6M FY2019 FY2020 revenue 8.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-004145 FY2020 net income -448.7M · NetIncomeLossAvailableToCommonStockholdersBasic, 0000950170-23-004145 8.2M FY2020 FY2021 revenue 69.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-018811 FY2021 net income -562.5M · NetIncomeLossAvailableToCommonStockholdersBasic, 0000950170-24-018811 69.7M FY2021 FY2022 revenue 77.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-024119 FY2022 net income -481.2M · NetIncomeLossAvailableToCommonStockholdersBasic, 0000950170-25-024119 77.6M FY2022 FY2023 revenue 9.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001743881-26-000009 FY2023 net income -643.2M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001743881-26-000009 9.3M FY2023 FY2024 revenue 221.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001743881-26-000009 FY2024 net income -535.8M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001743881-26-000009 221.9M FY2024 FY2025 revenue 502.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001743881-26-000009 FY2025 net income -724.9M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001743881-26-000009 502.1M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2019 to FY2025 (6 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $797.7M
  • − All liabilities $3.0B
  • = Net current asset value -$2.2B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $2.1B
  • − Other intangible assets $28.1M
  • = Tangible book value -$2.1B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

BBIO against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+126%5th of 155 · median +10.5%
Net margin
-4.1%15.3%
-62.6%140th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-39.1%130th of 145 · median 10.0%
BBIO and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
BBIO BridgeBio Pharma, Inc.$945.5M +126%94.3%-62.6%--39.1%-
CORT Corcept Therapeutics Inc$963.6M +12.8%-16.8%19.5%20.2%-
BCRX Biocryst Pharmaceuticals Inc$961.5M +94.1%97.8%-37.4%-38.0%-
IONS Ionis Pharmaceuticals Inc$960.1M +33.8%--56.9%-138.8%-64.2%4.60
WRBY Warby Parker Inc.$934.7M +13.0%54.7%0.8%1.9%2.3%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
All 162 companies in the group

Where the $502.1M of revenue came from

by product, year to Dec 31, 2025

  • Net product revenue $362.4M · 72%
  • License and services revenue $128.3M · 26%
  • Royalty revenue $11.4M · 2%

From the segment tables in the 10-K XBRL.

Profitability

  • Net margin below the peer median
    -62.6% vs 6.8%
  • A profit in 0 of 7 years
Net margin, FY2019 to FY2025: -642.5% to -144.4%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -9.9× interest expense
  • Equity below zero
    Debt $2.6B, equity −$1.7B
  • Current assets cover current liabilities
    Current ratio 2.09
Debt / equity at each year end, FY2019 to FY2025: 0.23 to 1.62

Cash and shareholders

  • Free cash flow positive in 0 of 7 years
    −$447.0M last year
  • Share count up over 5 years
    +62.3%
Free cash flow, FY2019 to FY2025: -256.2M to -447.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.6B of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $13.7M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · -38.3% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

BBIO's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue502.1M
FY2017: -FY2018: -FY2019: 40.6MFY2020: 8.2MFY2021: 69.7MFY2022: 77.6MFY2023: 9.3MFY2024: 221.9MFY2025: 502.1M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-724.9M
FY2017: -30.6MFY2018: -130.7MFY2019: -260.6MFY2020: -448.7MFY2021: -562.5MFY2022: -481.2MFY2023: -643.2MFY2024: -535.8MFY2025: -724.9M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-447.0M
FY2017: -41.0MFY2018: -138.8MFY2019: -256.2MFY2020: -407.2MFY2021: -511.2MFY2022: -424.3MFY2023: -529.0MFY2024: -521.7MFY2025: -447.0M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-580.0M
FY2017: -42.8MFY2018: -144.9MFY2019: -277.6MFY2020: -465.7MFY2021: -610.7MFY2022: -515.9MFY2023: -637.7MFY2024: -617.5MFY2025: -580.0M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-3.78
FY2017: -1.00FY2018: -2.12FY2019: -2.48FY2020: -3.80FY2021: -3.90FY2022: -3.26FY2023: -3.95FY2024: -2.88FY2025: -3.78 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares191.5M
FY2017: -FY2018: -FY2019: -FY2020: 118.0MFY2021: 144.4MFY2022: 147.5MFY2023: 162.8MFY2024: 186.1MFY2025: 191.5M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Net product revenue 362.4M72.2% +12465%
License and services revenue 128.3M25.6% -41.4%
Royalty revenue 11.4M2.3% +6637%

10-K 0001743881-26-000009, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue--40.6M8.2M69.7M77.6M9.3M221.9M502.1M
Cost of revenue----3.1M3.4M2.4M3.9M21.0M
R&D30.6M140.1M209.9M337.0M451.0M399.5M455.7M506.5M452.0M
SG&A13.3M43.6M94.4M145.7M192.2M143.2M150.6M288.9M531.2M
Operating income-43.9M-183.7M-266.2M-474.5M-576.6M-512.2M-607.4M-593.0M-523.4M
Interest expense13K2.5M8.8M36.7M46.8M80.4M81.3M91.0M53.1M
Pretax income43.8M169.5M288.6M505.5M-586.5M-484.7M-653.3M-542.2M-732.5M
Income tax-----001.2M435K
Net income-30.6M-130.7M-260.6M-448.7M-562.5M-481.2M-643.2M-535.8M-724.9M
EPS (diluted)-1.00-2.12-2.48-3.80-3.90-3.26-3.95-2.88-3.78
Diluted shares---118.0M144.4M147.5M162.8M186.1M191.5M
Depreciation & amortization--859K1.5M5.8M6.8M6.5M6.1M5.4M
EBITDA---265.4M-473.0M-570.8M-505.4M-600.9M-586.9M-518.0M
Operating margin---656.4%-5752.0%-827.1%-659.6%-6528.8%-267.2%-104.2%
Net margin---642.5%-5439.7%-806.9%-619.7%-6913.9%-241.4%-144.4%
Revenue growth----79.7%+745%+11.4%-88.0%+2285%+126%

Balance sheet

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash92.0M436.1M363.8M356.1M393.8M376.7M375.9M681.1M570.1M
Short-term investments--182.2M251.0M393.7M51.6M0017.4M
Receivables------1.8M4.7M139.4M
Inventory-------026.8M
Current assets-445.2M568.6M642.8M888.9M548.9M477.6M720.7M797.7M
Property & equipment-1.6M5.6M20.3M30.1M14.6M11.8M7.0M5.4M
Other intangible assets---044.9M28.7M26.3M23.9M28.1M
Total assets-464.9M631.7M703.6M1.0B623.0M546.4M919.3M936.0M
Accounts payable-13.5M8.9M8.9M11.9M11.6M10.7M9.6M36.2M
Current liabilities-32.6M60.4M95.6M135.1M121.4M143.8M154.4M288.0M
Total debt-54.5M95.4M93.9M430.8M431.0M446.4M437.3M2.0B
Total liabilities-87.6M155.7M595.7M1.9B1.9B1.9B2.4B3.0B
Shareholders' equity85.9M314.9M408.5M57.9M-870.4M-1.3B-1.4B-1.5B-2.1B
Retained earnings-48.7M-179.4M-440.0M-888.8M-1.4B-1.9B-2.6B-3.1B-3.8B

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-40.5M-136.6M-253.6M-399.7M-497.9M-419.5M-527.7M-520.7M-445.9M
Capital spending464K2.2M2.6M7.5M13.2M4.8M1.3M933K1.1M
Free cash flow-41.0M-138.8M-256.2M-407.2M-511.2M-424.3M-529.0M-521.7M-447.0M
Stock-based pay (added back)1.8M6.1M21.4M58.5M99.5M91.6M108.7M95.8M133.0M
Free cash flow after stock pay-42.8M-144.9M-277.6M-465.7M-610.7M-515.9M-637.7M-617.5M-580.0M
Dividends paid1.2M-997K------
Buybacks---75.0M200.0M00048.3M
Debt raised4.0M1.0M36.9M0456.3M00450.0M-
Debt repaid-1.1M-0124.1M20.5M0473.4M-
Investing cash flow-464K-21.0M-217.3M-53.0M-200.8M453.1M54.0M60.8M-24.5M
Financing cash flow113.0M501.5M398.8M447.2M736.4M-13.1M451.5M748.5M359.3M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.8M6.1M21.4M58.5M99.5M91.6M108.7M95.8M133.0M
Stock-based pay / revenue--52.7%708.7%142.7%117.9%1168.5%43.2%26.5%
Operating lease cost---3.8M5.6M5.2M4.0M4.1M4.9M
Operating lease cash paid--2.0M4.2M6.1M6.2M4.8M5.1M6.5M
Finance lease principal paid---25K-----
Right-of-use assets--10.0M16.5M15.9M10.7M8.0M5.8M8.1M
Operating lease liabilities---18.5M22.4M15.9M13.1M9.2M10.0M
Finance lease liabilities---1.7M1.5M----

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BBIO/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.